|
How might
vitamin E supplements benefit a person with
Alzheimer’s disease?
The normal cell function termed “oxidative metabolism” results in byproducts
known as free radicals. Free radicals are highly reactive compounds that quickly
“attack” other cell substances, causing damage to the cell wall, metabolic
machinery, and genetic material (DNA). The cells have natural defenses against
this damage, which include the antioxidants vitamins C and E, but with age some
of these protective mechanisms decline. Brain cell damage caused by free
radicals may play a role in Alzheimer’s disease.
What was the result of the multicenter national study of vitamin E and
Alzheimer’s disease?
Research reported in the April 24, 1997, issue of the New England Journal of
Medicine investigated the effectiveness of vitamin E and selegiline, a drug with
antioxidant properties that is prescribed for treating Parkinson’s disease. The
research was part of the Alzheimer’s Disease Cooperative Study, a consortium of
academic Alzheimer research centers sponsored by the U.S. National Institute on
Aging. The study suggests that either selegiline or vitamin E delays the
occurrence in patients with Alzheimer’s disease to one or more of the following
“endpoints”: death, institutionalization, progression from moderate to severe
dementia, or loss of ability to perform two of three basic activities of daily
living (eating,
grooming, or toileting). When both agents were given together,
there was also a delay in progression of Alzheimer’s disease as measured by
these endpoints. However, both agents together did not help more than either
drug alone. These agents did not improve memory and thinking test scores.
These results are encouraging but as yet have not been confirmed by other
studies. We also do not know if these agents would be helpful in milder or
severe stages of Alzheimer’s disease. There was no evidence that intellectual
deterioration was slowed. Finally, any medication may have side effects or
potential interactions with other drugs. For example, it is known that certain
doses of selegiline (higher than those used in the study) can lead to serious
interactions with some types of foods and certain medications.
Should vitamin E be prescribed?
Vitamin E worked at least as well as selegiline on Alzheimer’s progression in
this study and had fewer side effects. Vitamin E also costs less. For these
reasons it is preferred over selegiline in Alzheimer’s disease treatment.
Vitamin E is considered to be a “benign” medication and most people can take it
without side effects. However, any change in medications should first be
discussed with your primary care physician because all medication can cause side
effects or interactions with other medications. People taking “blood-thinners”
like warfarin (Coumadin®), ticlopidine (Ticlid®), and others may not be able to
take Vitamin E or will need to be monitored closely by their physician if they
are taking Vitamin E.
What dose of vitamin E is appropriate?
Exactly what dose of vitamin E is the “best” is not known. The doses of
vitamin E in the study were 2,000 IU daily. Other doses need to be studied to
answer this question confidently. Many doctors recommend 400 IU twice daily
because they believe this dosage to be safe for most individuals and it should
have the antioxidant effect desired in the brain.
Are there other drugs available to treat symptoms of Alzheimer’s?
The first Alzheimer medications approved by the U.S. Food and Drug
Administration (FDA) were cholinesterase (KOH luh NES ter ays) inhibitors. Three
of these drugs are commonly prescribed — Donepezil (Aricept), approved in 1996; Rivastigmine (Exelon), approved in 2000; and Galantamine (Razadyne) (approved in 2001
under the trade name Reminyl® and renamed Razadyne in 2005). Tacrine (Cognex®),
the first cholinesterase inhibitor, was approved in 1993 but is rarely
prescribed today because of associated side effects, including possible liver
damage. All of these drugs work by preventing the breakdown of acetylcholine
(pronounced a SEA til KOH lean), a chemical messenger in the brain that is
important for memory and other thinking skills.
Memantine, approved in 2003, is classified as an uncompetitive
low-to-moderate affinity N-methyl-D-aspartate (NMDA) receptor antagonist, the
first Alzheimer drug of this type approved in the United States. It appears to
work by regulating the activity of glutamate, another of the brain’s specialized
messenger chemicals involved in information processing, storage and retrieval.
There are also several experimental Alzheimer drugs under investigation at
study sites nationwide. To obtain information about FDA-approved medications or
investigational drugs, please call 1.800.272.3900 or visit our Web site at
http://www.alz.org.
What other help is available for people with Alzheimer’s disease and their
families?
Through their collective experience, families and professional caregivers
have developed a wide range of strategies to help manage symptoms of Alzheimer’s
disease and to help reduce its impact on affected individuals, families, and
friends. Helpful strategies include environmental and behavioral modifications,
activity programs, and support and respite services.
To obtain further information about these approaches and to learn about
resources in your community, contact your local chapter of the Alzheimer’s
Association.
top .
send to friend .
alzheimer's site
map
Reviewed: 02/2006
|
REALMENTALHEALTH CARE PROVIDER DIRECTORY
Find a Local Therapist
|
|